Wako, Japan

Kenichi Washizuka



 

Average Co-Inventor Count = 9.1

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2022-2023

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Kenichi Washizuka: Innovator in Pharmaceutical Compounds

Introduction

Kenichi Washizuka is a notable inventor based in Wako, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have potential therapeutic applications. With a total of two patents to his name, Washizuka's work is recognized for its innovative approach to cell growth inhibition.

Latest Patents

Washizuka's latest patents include a dihydroquinazolinone compound or pharmacologically acceptable salt. This invention focuses on a cell growth inhibitor that comprises a compound of a specific formula or a pharmacologically acceptable salt thereof. Additionally, he has developed 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts, characterized by various spiro structures that enhance their pharmacological properties.

Career Highlights

Throughout his career, Kenichi Washizuka has worked with prominent organizations such as Riken Corporation and the Japanese Foundation for Cancer Research. His experience in these institutions has allowed him to refine his expertise in pharmaceutical research and development.

Collaborations

Washizuka has collaborated with esteemed colleagues, including Minoru Yoshida and Hiroyuki Seimiya. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Kenichi Washizuka's contributions to pharmaceutical innovation highlight his role as a key inventor in the field. His patents reflect a commitment to advancing medical science through the development of effective therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…